// App-Quantinova.ai

1491 : IPH4301, an antibody targeting MICA and MICB exhibits potent cytotoxic activity and immunomodulatory properties for the treatment of cancer

Researchers

Presenter

  • Ariane Morel

Principal Investigators

  • Cecile Bonnafous

  • Sylvia Trichard

  • Alix Joulin-Giet

  • Samia Mizari

  • Gwendoline Grondin

  • Nadia Anceriz

  • J. Zhang

  • J. Jarzen

  • J. Wu

  • Laetitia Cohen-Tannoudji

  • Yannis Morel

  • Benjamin Rossi

  • Carine Paturel

  • Renaud Buffet

  • Laurent Gauthier

  • Nicolai Wagtmann

  • Mathieu Blery

Medical Centers

  • Innate Pharma, Marseille, France

  • Medcl Univ of South Carolina, Charleston, SC

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Natural killer group 2D

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved